Q1 2014 13F Holders as of 31 Mar 2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
11,832,924
-
Share change
-
+11,832,924
-
Total reported value
-
$372,736,175
-
Price per share
-
$31.50
-
Number of holders
-
65
-
Value change
-
+$372,736,179
-
Number of buys
-
65
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2014
As of 31 Mar 2014,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,832,924 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., Visium Asset Management, LP, WADDELL & REED FINANCIAL INC, COLUMBIA WANGER ASSET MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, Partner Fund Management, L.P., RS INVESTMENT MANAGEMENT CO LLC, FMR LLC, Camber Capital Management LLC, and Zweig-DiMenna Associates LLC.
This page lists
65
institutional shareholders reporting positions in this security
for the Q1 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.